2024
DOI: 10.1038/s41408-024-01191-8
|View full text |Cite
|
Sign up to set email alerts
|

CAR-T cell therapy in Multiple Myeloma: current status and future challenges

Dawn Swan,
Deepu Madduri,
Jay Hocking

Abstract: The treatment of multiple myeloma has changed dramatically in recent years, with huge strides forward made in the field. Chimeric antigen receptor T-cell therapy targeting the B cell maturation antigen (BCMA) is now widely approved in relapsed refractory patients and is moving into earlier treatment lines. In this review, we discuss the evidence underpinning current regulatory approvals and consider mechanisms through which CAR-T cell efficacy could be improved. These include tackling BCMA-loss, harnessing the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 136 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?